Product Description
Trilaciclib dihydrochloride is a CDK4/6 inhibitor which reduces chemotherapy-induced myelosuppression. It induces a G1 cell-cycle arrest in CDK4/6-dependent HS68 cells with an EC₅₀ of 30 nM. It is used to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy.
Trilaciclib dihydrochloride is a CDK4/6 inhibitor which reduces chemotherapy-induced myelosuppression. It induces a G1 cell-cycle arrest in CDK4/6-dependent HS68 cells with an EC₅₀ of 30 nM. It is used to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy.
Biovision | B3120 | Trilaciclib dihydrochloride DataSheet
Alternate Name/Synonyms: G1T28 dihydrochloride; 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one;dihydrochloride
Appearance: Solid
Formulation:
CAS Number: 1977495-97-8
Structure Available?: TRUE
Peptide sequence:
Salt Form: TRUE
Molecular Formula: C₂₄H₃₂Cl₂N₈O
Molecular Weight: 519.5
Cell-Permeable?: True
Purity: ≥ 97%
Solubilities: ~1 mg/ml in DMSO (may need ultrasonication)
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: A CDK4/6 inhibitor which reduces chemotherapy-induced myelosuppression
MDL Number: MFCD31630829
PubChem CID: 124081865
SMILES: CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6.Cl.Cl
InChi: InChI=1S/C24H30N8O.2ClH/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23;;/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29);2*1H
InChi Key: BRCYOXKEDFAUSA-UHFFFAOYSA-N